Skip to main content
. Author manuscript; available in PMC: 2013 Apr 17.
Published in final edited form as: J Immunol. 2008 Jun 1;180(11):7212–7220. doi: 10.4049/jimmunol.180.11.7212

FIGURE 8.

FIGURE 8

Effect of inhibitors of MAPK pathways on NECA-dependent IL-13 and VEGF secretion from BMMCs and HMC-1 cells. A, Western blot analysis of phosphorylation of ERK and p38 MAPK (phospho-ERK and phospho-p38, respectively) in BMMCs and HMC-1 cells that were either not stimulated (−) or stimulated with 10 μM NECA for the indicated time period. Equal loading of proteins was verified by reprobing the same blot with total ERK and p38 MAPK Abs (ERK and p38, respectively). Blots are representative of three experiments. Effects of MEK inhibitor UO126 (●) and its inactive analog UO124 (○) on IL-13 (B) or VEGF (D) secretion from HMC-1 cells stimulated with 10 μM NECA. Values are presented as mean percentage ± SEM of NECA-stimulated response from three experiments. Effects of p38 inhibitor SB202190 (●) and its inactive analog SB202474 (○) on IL-13 (C) or VEGF (E) secretion from HMC-1 cells stimulated with 10 μM NECA. Values are presented as mean percentage ± SEM of NECA-stimulated response from three experiments. F, Effects of MEK inhibitor UO126 (10 μM), p38 inhibitor SB202190 (10 μM), and their inactive analogs UO124 (10 μM) and SB202474 (10 μM), respectively, on IL-13 secretion from BMMCs stimulated with 10 μM NECA. Significant difference (p < 0.05) was determined by one-way ANOVA. Data are expressed as the percentage of NECA-stimulated response and presented as mean ± SEM of three separate cell preparations. G, Effects of MEK inhibitor UO124 (10 μM), p38 inhibitor SB202190 (10 μM), and their inactive analogs UO126 (10 μM) and SB202474 (10 μM) on VEGF secretion from BMMCs stimulated with 10 μM NECA. Significant difference (p < 0.001) was determined by one-way ANOVA. Data are expressed as the percentage of NECA-stimulated response and presented as mean ± SEM of three separate cell preparations.